PositiveID to collaborate with NASA on biological detection
Under the terms of the agreement, NASA will assess the company's Firefly Dx technology for potential space and ground applications. PositiveID will assess the technology to improve the development of Firefly hardware for extreme environments, such as field applications for the Department of Defense.
"We are very proud to collaborate with NASA's world-class team of scientists and researchers on the continued development of Firefly to advance mission-critical applications for point-of-need diagnostics, both in space and on the front lines to protect our nation from future bioterrorism threats," William Caragol, the chairman and CEO of PositiveID, said.
Firefly Dx is a handheld, point-of-need system meant to deliver molecular diagnostic results using real-time TaqMan polymerase chain reaction chemistry. Firefly delivers results from a sample in less than 20 minutes, potentially allowing for more rapid and effective treatment than what is available with current systems.
PositiveID is developing Firefly to meet the need for more rapid and accurate point-of-need diagnostics to help first responders, hospitals and other providers to save lives. The company develops microfluidic systems for the automated preparation and performance of biological assays to detect threats and analyze samples.